antiviral news

Press Releases in the global landscape

Nov 18, 2024

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo.

Nov 14, 2024

Xocova Price to Be Trimmed by 300 Yen after CEA; No Change for Mounjaro

Japan will trim the NHI price of Shionogi’s oral COVID-19 treatment Xocova (ensitrelvir) by some 300 yen in February next year under the cost-effectiveness assessment (CEA) scheme, a key reimbursement policy panel agreed on November 13.

Nov 11, 2024

Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief, studies find

The antiviral drug was also found to lead to a reduction in the use of healthcare resources.

Nov 7, 2024

Gilead beats Covid drug sales forecasts, takes $1.75B hit on Trodelvy study fail

Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall Street analysts had projected.

Nov 5, 2024

Shionogi finds positive data on ensitrelvir for COVID-19

Phase III Scorpio-PEP study results showed Shionogi & Co. Ltd.’s oral antiviral ensitrelvir fumaric acid (Xocova) reduced risk of symptomatic COVID-19 infection in subjects who were exposed to the virus by infected household members.

Nov 4, 2024

Metformin May Reduce Long COVID in Non-Diabetic Population

Metformin prescribed within a week of SARS-CoV-2 infection was associated with a 53% reduction in long COVID or death over 6 months in people without diabetes or prediabetes, according to data presented at the Infectious Disease Week (IDWeek) 2024 Annual Meeting.